Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SOM230C · 1 trial · 1 indication
Progression is defined using Modified Macdonald Criteria , using a \>/= 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR clear clinical worsening or failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer).
| Arm | Type | Description |
|---|---|---|
| SOM230C | EXPERIMENTAL | Monthly SOM230C (pasireotide LAR) - 60 mg intramuscularly (Single-Arm Trial) |
| Name | Type | Description |
|---|---|---|
| SOM230C | DRUG | Injection in the buttocks every 28 days |
Inclusion Criteria: * 18 years of age or older * Radiographically measurable disease on contrast-enhanced MRI or CT images * Karnofsky Performance status of 60 or greater * Life expectancy of at least 3 months * Histologically confirmed diagnosis of recurrent or progressive intracranial meningioma(...
SOM230C is an investigational small molecule being studied for the treatment of recurrent or progressive meningioma. It is in Phase 2 clinical development and has been evaluated in a completed clinical trial in the United States.
SOM230C is being developed by Novartis AG, which trades on the New York Stock Exchange under the ticker NVS. The company is conducting clinical research on this investigational small molecule for meningioma.
SOM230C is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities, and it is being studied for the treatment of recurrent or progressive meningioma.
SOM230C has been studied in one completed Phase 2 clinical trial with the identifier NCT00859040, titled 'Monthly SOM230C for Recurrent or Progressive Meningioma.' The trial enrolled 34 adult participants in the United States and was not randomized or blinded.
SOM230C is an alternative name for pasireotide, a small molecule developed by Novartis AG. In clinical research, it has been investigated under the name SOM230C for the treatment of recurrent or progressive meningioma.